These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 4754539)

  • 21. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
    Parkes JD; Baxter RC; Marsden CD; Rees JE
    J Neurol Neurosurg Psychiatry; 1974 Apr; 37(4):422-6. PubMed ID: 4838913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug management of Parkinson's disease.
    Kishore A; Snow BJ
    Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 24. The treatment of parkinsonism with L-Dopa and amantadine.
    Green J
    J Fla Med Assoc; 1970 Jun; 57(6):28-33. PubMed ID: 5445813
    [No Abstract]   [Full Text] [Related]  

  • 25. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
    Birkmayer W
    Wien Klin Wochenschr; 1969 Sep; 81(39):677-9. PubMed ID: 5344299
    [No Abstract]   [Full Text] [Related]  

  • 26. [Attempt at treating parkinsonism with L-dopa and Artane].
    Stelmasiak Z; Lackowska H; Maksymowicz B
    Pol Tyg Lek; 1971 Aug; 26(34):1325-6. PubMed ID: 5110789
    [No Abstract]   [Full Text] [Related]  

  • 27. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 28. [6 months of treatment with amantadine and L-Dopa. Comparison in 2 groups of patients with parkinsonism].
    Buscaino GA; Campanella G; Zallone E
    Minerva Med; 1971 Oct; 62(82):3974-8. PubMed ID: 5125057
    [No Abstract]   [Full Text] [Related]  

  • 29. [The antiparkinson activity of gludantan (preliminary report)].
    Kamianov IM; Andrezinia RA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1975; 75(6):910-6. PubMed ID: 1217399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current treatment of Parkinsonism with amantadine hydrochloride].
    Gerstenbrand F; Gründig E; Musiol A
    Pol Tyg Lek; 1972 Jul; 27(23):878-9. PubMed ID: 5040531
    [No Abstract]   [Full Text] [Related]  

  • 31. New approaches in the treatment of parkinsonism.
    JAMA; 1969 Sep; 209(9):1358-9. PubMed ID: 5819907
    [No Abstract]   [Full Text] [Related]  

  • 32. Levodopa and amantadine in the treatment of Parkinsonism.
    Critchley E
    Practitioner; 1972 Apr; 208(246):499-504. PubMed ID: 5031037
    [No Abstract]   [Full Text] [Related]  

  • 33. [Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
    Evtushenko SK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Dec; 76(12):1797-1802. PubMed ID: 1015115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 35. [Current treatment of the Parkinsonian syndrome].
    Voiculescu V
    Neurol Psihiatr Neurochir; 1973; 18(6):519-23. PubMed ID: 4790485
    [No Abstract]   [Full Text] [Related]  

  • 36. [Kr 339 in the treatment of parkinsonian tremor].
    Iivanainen M
    Duodecim; 1974; 90(8):590-6. PubMed ID: 4605767
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pathochemical bases for the treatment of parkinsonism].
    Petelin LS; Tret'iakova KA; Pigarev VA; Romenskaia LK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1971 Dec; 71(12):1765-70. PubMed ID: 5143959
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 40. [The treatment of parkinsonism with amantadine].
    Völler GW
    Dtsch Med Wochenschr; 1970 Apr; 95(17):934-7. PubMed ID: 5439551
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.